Collaboration - April 15, 2015
LDC, Astra Expand Alliance
The Lead Discovery Center GmbH (LDC) and AstraZeneca have expanded their alliance to discover new medicines for the treatment of diseases with high unmet medical need, according to report published on BioSpace.com. Through an additional three-year period of collaboration, AstraZeneca expects to provide an extended set of high-quality compounds to the LDC’s internal screening collection […]
Companies - April 15, 2015
Elocta Gets Orphan Status
Swedish Orphan Biovitrum AB has received orphan drug designation in Switzerland for its long acting hemophilia drug candidate Elocta (rFVIIIFc), developed for the treatment of hemophilia A. An orphan drug designation encourages the development of medicines for rare diseases and provides orphan status to drugs and biologics under development. Elocta is a long-acting recombinant factor […]
Companies - April 15, 2015
Novo Extends Diabetes Aid
Novo Nordisk has extended its Changing Diabetes® in Children program for another three years, according to a company announcement. Since 2009, the company has provided free insulin and access to diabetes care to more than 13,000 children in nine countries in Africa and Southeast Asia. In addition, 108 diabetes clinics have been established and 5,479 healthcare […]
Uncategorized - April 10, 2015
Breast Cancer Predictor Devised
Scientists have devised a new method for predicting whether a woman will develop breast cancer within two to five years. “The method may not be perfect, but it’s seriously good,” says Rasmus Bro, co-author of the study and professor of chemometrics at the Department of Food Science at the University of Copenhagen. “At the same […]
Pharma Business - April 9, 2015
Enzymatics to Elect Board
Prior to the Enzymatics annual general meeting scheduled for April 21, the nominating committee proposed the re-election of three members of the board of directors and the election of another three. Proposed for re-election are Christian W. Jansson, Marianne Dicander and Anders Jungbeck. New candidates are Monica Wallter, who is the CEO of Lidds; Nils Siegbahn, […]
Drug Development Pharma - April 9, 2015
FDA Accepts Novo Resubmission
The US Food and Drug Administration (FDA) has accepted for review Novo Nordisk’s Class II Resubmissions for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart). To preserve the integrity of the ongoing DEVOTE trial, only a small team within Novo Nordisk has access to the data, according to the company. This team has prepared the interim analysis […]
